• Corpus ID: 231879556

Artificial Intelligence based Autonomous Molecular Design for Medical Therapeutic: A Perspective

@article{Joshi2021ArtificialIB,
  title={Artificial Intelligence based Autonomous Molecular Design for Medical Therapeutic: A Perspective},
  author={Rajendra Prasad Joshi and Neeraj Kumar},
  journal={ArXiv},
  year={2021},
  volume={abs/2102.06045}
}
Domain-aware machine learning (ML) models have been increasingly adopted for accelerating small molecule therapeutic design in the recent years. These models have been enabled by significant advancement in state-of-the-art artificial intelligence (AI) and computing infrastructures. Several ML architectures are predominantly and independently used either for predicting the properties of small molecules, or for generating lead therapeutic candidates. Synergetically using these individual… 

Figures and Tables from this paper

Evening the Score: Targeting SARS-CoV-2 Protease Inhibition in Graph Generative Models for Therapeutic Candidates

A pair of graph generative models are examined for the therapeutic design of novel drug candidates targeting SARS-CoV-2 viral proteins with unique strengths: an autoencoder that generates molecules with similar structures to a dataset of drugs with anti-SARS activity and a reinforcement learning algorithm that generates highly novel molecules.

3D-Scaffold: Deep Learning Framework to Generate 3D Coordinates of Drug-like Molecules with Desired Scaffolds

The proposed 3D-Scaffold framework generates predominantly valid, unique, novel, and experimentally synthesizable molecules that have drug-like properties similar to the molecules in the training set and generalizes to new scaffolds, making it applicable to other domains.

References

SHOWING 1-10 OF 116 REFERENCES

Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis

How predictive models can be integrated into medicinal chemistry synthesis workflows, how they are currently used within MLPDS member companies, and the outlook for this field are shared.

De novo generation of hit-like molecules from gene expression signatures using artificial intelligence

A generative model that bridges systems biology and molecular design, conditioning a generative adversarial network with transcriptomic data that can automatically design molecules that have a high probability to induce a desired transcriptomic profile.

Deep Reinforcement Learning for Multiparameter Optimization in de novo Drug Design

A fragment-based reinforcement learning approach based on an actor-critic model for the generation of novel molecules with optimal properties for medicinal chemistry programs, demonstrating that 93% of the generated molecules are chemically valid and more than a third satisfy the targeted objectives.

A deep-learning view of chemical space designed to facilitate drug discovery

A deep neural network model that advances the state of the art in machine learning approaches to molecular design is presented, and the ability of DESMILES to hone molecular properties is explained and demonstrated.

Deep reinforcement learning for de novo drug design

The ReLeaSE method is used to design chemical libraries with a bias toward structural complexity or toward compounds with maximal, minimal, or specific range of physical properties, such as melting point or hydrophobicity.

Reinforced Adversarial Neural Computer for de Novo Molecular Design

An original deep neural network (DNN) architecture named RANC (Reinforced Adversarial Neural Computer) for the de novo design of novel small-molecule organic structures based on the generative adversarial network (GAN) paradigm and reinforcement learning (RL).

Molecular de-novo design through deep reinforcement learning

A method to tune a sequence-based generative model for molecular de novo design that through augmented episodic likelihood can learn to generate structures with certain specified desirable properties is introduced.

DeepScaffold: a comprehensive tool for scaffold-based de novo drug discovery using deep learning

A scaffold-based molecular generative model for drug discovery is proposed, which performs molecule generation based on a wide spectrum of scaffold definitions, including Bemis-Murko (BM) scaffolds, cyclic skeletons, and scaffolds with specifications on side-chain properties.

AMPL: A Data-Driven Modeling Pipeline for Drug Discovery

The ATOM Modeling PipeLine, or AMPL, extends the functionality of the open source library DeepChem and supports an array of ML and molecular featurization tools and indicates that traditional molecular fingerprints underperform other feature representation methods.
...